Prognostic Model Based on Sex, ALBI Grade, and ALR in Intermediate-to-Advanced HCC Patients Receiving Targeted Therapy Combined with ICIs and Interventional Treatment
Xiaomeng Hu, Huiying Yan, Siyi Li, Zhiqiang Han, Hua Li, Xi Wei, Wei Zhang, Huikai Li · 2026
Read Prognostic Model Based on Sex, ALBI Grade, and ALR in Intermediate-to-Advanced HCC Patients Receiving Targeted Therapy Combined with ICIs and Interventional Treatment by Xiaomeng Hu, Huiying Yan, Siyi Li, Zhiqiang Han, Hua Li, Xi Wei, Wei Zhang, Huikai Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13359942.txt.
Description
Xiaomeng Hu and co-authors build a simple survival model for advanced liver cancer in a 2026 study. Patients at middle to late stages now often receive a triple mix: targeted drugs, immune therapy, and procedures that block the tumor's blood supply. Results still vary widely between patients. The team sought a forecast from facts already in the chart.
Using data from 184 patients, they built a model on three items: sex, a liver function grade called ALBI, and a blood ratio called ALR. The model split patients into clearly different outlook groups. A tool this simple could help doctors stratify risk and tailor how aggressively each patient is treated.
Catalog record
| CREATOR | Xiaomeng Hu, Huiying Yan, Siyi Li, Zhiqiang Han, Hua Li, Xi Wei, Wei Zhang, Huikai Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27311 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |